AstraZeneca’s Fasenra misses primary endpoint in COPD trial but keeps investor confidence alive

AstraZeneca plc (LON: AZN) closed trading on the London Stock Exchange at 11,396.00 GBX on 17 September 2025, up 0.44% (50 points) from the previous session. The modest gain came despite the company confirming that its RESOLUTE Phase III trial of Fasenra (benralizumab) in chronic obstructive pulmonary disease (COPD) patients did not achieve statistical significance on its primary endpoint. While numerical improvements were observed, the trial fell short of demonstrating the efficacy needed to broaden Fasenra’s current label in severe asthma and eosinophilic-driven conditions.

The trial outcome is significant given the high prevalence of COPD, which affects more than 391 million people globally, and AstraZeneca’s strategic push to reinforce its leadership in respiratory and immunology. However, investor sentiment suggests confidence that the company’s diversified pipeline and commercial base will cushion the impact of this setback.

Why did AstraZeneca’s RESOLUTE Phase III trial results matter for COPD drug development?

The RESOLUTE study was a large-scale, double-blind, placebo-controlled Phase III trial designed to evaluate whether benralizumab could reduce exacerbations in patients with moderate to very severe COPD who had high eosinophil counts and a history of frequent flare-ups. Conducted across a population of 689 participants, the trial required that all patients remained on background inhaled therapies (ICS/LABA/LAMA) and had at least two exacerbations in the prior year.

The primary endpoint measured the annualised rate of moderate or severe exacerbations, defined as worsening COPD requiring systemic corticosteroids, antibiotics, or hospitalisation. While the drug showed numerical benefit, the difference compared to placebo was not statistically significant. This echoes outcomes from AstraZeneca’s earlier GALATHEA and TERRANOVA trials, which also indicated limited benefit of anti-IL-5 therapies in COPD.

COPD remains an urgent area of unmet need. Exacerbations are often life-threatening and lead to irreversible lung damage, increased hospitalisation, and higher mortality risk. By targeting eosinophils—white blood cells implicated in inflammation—AstraZeneca hoped to replicate Fasenra’s proven asthma efficacy in COPD. The mixed results reinforce the complexity of COPD, which is now widely seen as a heterogeneous disease requiring multiple therapeutic approaches.

How does Fasenra fit into AstraZeneca’s broader respiratory and immunology strategy?

Fasenra is already a commercial success in other indications. It is approved in over 80 countries as an add-on maintenance therapy for severe eosinophilic asthma, including in the US, EU, Japan, and China. More than 150,000 patients worldwide are currently prescribed the drug. Fasenra is also approved for eosinophilic granulomatosis with polyangiitis (EGPA) in more than 60 countries and is under review for hypereosinophilic syndrome (HES) following positive Phase III results from the NATRON trial.

AstraZeneca’s respiratory and immunology division is a major growth engine, with a 50-year legacy in inhaled and biologic medicines. Fasenra was developed in collaboration with Kyowa Kirin Co., Ltd. and in-licensed via its subsidiary BioWa, Inc. The drug’s mechanism of action—eliminating eosinophils via antibody-dependent cell-mediated cytotoxicity—has positioned it as a differentiated biologic in severe asthma, where competing therapies like GlaxoSmithKline’s (LON: GSK) Nucala and Sanofi/Regeneron’s (NASDAQ: SNY, NASDAQ: REGN) Dupixent are also active.

The RESOLUTE outcome does not diminish Fasenra’s commercial role in asthma and EGPA, but it likely closes the door to a multi-billion-dollar COPD expansion. AstraZeneca has stressed that it remains committed to developing new COPD therapies, with other biologics and small molecules progressing in its pipeline.

What does AstraZeneca’s stock movement reveal about investor sentiment?

On 17 September 2025, AstraZeneca shares moved up 0.44% to 11,396.00 GBX, with intraday highs of 11,400.00 GBX and lows of 11,246.00 GBX. The trading session indicated resilience despite the clinical disappointment.

Institutional investors appear to view the COPD miss as non-critical to AstraZeneca’s immediate revenue trajectory. Analysts note that the company derives the bulk of its sales from oncology drugs such as Tagrisso, Imfinzi, and Lynparza, alongside its cardiovascular and rare disease portfolio. Respiratory and immunology contribute meaningfully, but COPD expansion was never fully baked into consensus estimates.

From a technical perspective, AstraZeneca continues to trade near the upper end of its 52-week range, suggesting strong support levels. Buy-side desks report that foreign institutional investors (FIIs) have maintained exposure to the stock, while domestic institutional investors (DIIs) are selectively adding positions on weakness. Market chatter suggests a “Hold-to-Buy” sentiment, with analysts awaiting Q3 earnings updates for fresh catalysts.

Why is COPD such a high-stakes therapeutic area for biopharma companies?

COPD is the third leading cause of death globally, responsible for millions of fatalities annually. Unlike asthma, COPD is irreversible and progressive, primarily linked to smoking and environmental factors. Current treatment relies on inhaled corticosteroids and bronchodilators, but these therapies mainly manage symptoms rather than halt disease progression.

Biologics like benralizumab were hoped to revolutionize COPD care by addressing inflammatory pathways. However, trial outcomes from AstraZeneca and others show that COPD patients are a heterogeneous group—some respond to eosinophil-targeting therapies, but many do not. This variability complicates trial design and regulatory approval.

Competitors such as GlaxoSmithKline, Novartis, and Boehringer Ingelheim are also pursuing biologic approaches, with mixed results. The setback underscores the need for precision medicine in COPD, using biomarkers to better stratify patients. While RESOLUTE narrowed its inclusion criteria to high eosinophil counts, the data still failed to deliver statistical significance.

What is AstraZeneca’s future outlook in respiratory and immunology after the RESOLUTE trial?

Despite the RESOLUTE miss, AstraZeneca has reiterated its commitment to respiratory innovation. Its pipeline includes next-generation biologics, inhaled medicines, and new modalities targeting immune-mediated diseases. The company’s stated ambition is to eliminate asthma attacks, reduce COPD as a leading cause of death, and achieve remission in immune-driven conditions.

In the near term, investors will watch regulatory reviews of Fasenra in HES and potential label expansions in pediatric populations. The EGPA franchise is expected to grow as adoption widens globally. Analysts also highlight opportunities in novel oral therapies and digital inhaler platforms, where AstraZeneca has invested significantly.

Longer term, AstraZeneca’s diversified revenue mix—anchored by oncology, rare diseases (via Alexion), and cardiovascular therapies—provides resilience. COPD expansion would have been a bonus, not a lifeline. For now, the company’s R&D credibility remains intact, bolstered by its willingness to share data transparently with the scientific community.

How should investors interpret AstraZeneca’s latest trial update and stock sentiment?

The RESOLUTE trial outcome is a reminder of the scientific and commercial risks inherent in late-stage drug development. While Fasenra will not immediately expand into COPD, AstraZeneca’s existing approvals in asthma and EGPA continue to underpin a strong revenue base.

The stock’s upward movement following the announcement suggests that investors remain focused on the broader pipeline strength rather than a single trial. Market consensus indicates a neutral-to-positive outlook, with potential upside tied to upcoming oncology catalysts, regulatory milestones in rare diseases, and sustained momentum in respiratory and immunology.

For retail and institutional investors alike, AstraZeneca remains a defensive pharmaceutical stock with steady growth potential. The clinical disappointment in COPD underscores the need for patience in drug development, but the company’s diversified portfolio ensures that its long-term trajectory remains intact.